STAT3-INHIBITOREN
European patent · EP4070790 · In force
Register entry
- Publication number
- EP4070790
- Application number
- EP22161820
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Apr 18, 2019
- Published
- Oct 12, 2022
- Granted
- Jun 3, 2026
- Protection ends at the latest
- Apr 17, 2039
- Next annual fee due
- Apr 30, 2027
- IPC classes
- A61K 31/18 (2006.01)C07C 311/21 (2006.01)A61P 11/00 (2006.01)A61P 25/00 (2006.01)A61P 31/12 (2006.01)A61P 35/02 (2006.01)A61P 37/08 (2006.01)A61P 43/00 (2006.01)C07C 311/29 (2006.01)
- Priority
- US 201862659872 P 19.04.2018US 201962793491 P 17.01.2019
- Divided from
- EP19788688
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Jul 29, 2026
Owner
- Owner
- Tvardi Therapeutics, Inc., 3 Sugar Creek Center Boulevard, Suite 525, Sugar Land, TX 77478, USA, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030-3411, USA → Tvardi Operating Company, Inc., 3 Sugar Creek Center Boulevard, Suite 525, Sugar Land, TX 77478, USA, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030-3411, USA
Published in Swissreg on 29.07.2026
- Jun 3, 2026
Granted
- Specification status
- Non-published patent application → Granted patent
- Status of protective title
- Initiated → Active
Published in Swissreg on 03.06.2026
Parties
Holder
Inventor
WIED, Sofia De Achaval
77459 Missouri City, US
BAUTA, William E.
78230 San Antonio, US
CANTRELL, William R. Jr.
78253 San Antonio, US
TWEARDY, David John
77005 Houston, US
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.